Value-Based Care

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies.

Value-based care in oncology: why CMS’ models have fallen short and how new partners can sustain navigation, symptom monitoring, and savings.

Experts outline 4 roles within the value-based care ecosystem that will make it more cohesive and effective for patients.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

LLMs may improve pediatric clinical decision-making, but gaps in safety, accuracy, and pediatric-specific data remain.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

March marks the 10th anniversary of the CDC's opioid prescribing guidelines for patients with chronic pain, which were later updated to expand their scope.

Discussions about drug pricing require consideration of values and preferences, according to Jonathan D. Campbell, PhD, chief science officer of the National Pharmaceutical Council.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

Thyme Care bets on ePRO-driven toxicity monitoring to cut Medicare oncology adverse events, infections and ED visits—making value-based care finally work.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

Experts discussed how systemic changes need to be made to help improve preventive care access, which in turn can improve outcomes.

Accountable care experts say the future of value in Medicare will rely on scaling up innovation, emphasizing downstream prevention, and staying alert to waste.

The 2026 V-BID Summit showcases strategies to make health care more affordable, equitable, and outcomes-driven.

ACOs entering MSSP with higher spending were consistently more likely to earn bonuses—a gap that persisted after a 2017 benchmarking policy change.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Kevin Ma, PhD, discusses new data showing 2024–2025 COVID-19 vaccines reduced hospitalization and severe outcomes.

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone.

Over 15,000 NYC nurses ratified new contracts after a 41-day strike, securing staffing protections, salary increases, and safety reforms.

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants.

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes.

A systematic review finds that diagnostic discordance in bone and soft tissue sarcoma may reduce survival, supporting expert second opinions.